BioXcel Therapeutics Aktie

Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 72,046 shares of the company’s stock after acquiring an additional 48,336 shares during the quarter. Squarepoint Ops LLC owned about 0.15% of BioXcel Therapeutics worth $27,000 as of its most recent SEC filing. Several other institutional investors have also recently made changes to their positions in BTAI. Geode Capital Management LLC lifted its stake in shares of BioXcel Therapeutics by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 311,965 shares of the company’s stock worth $117,000 after purchasing an additional 13,922 shares during the period. Wells Fargo & Company MN raised its stake in BioXcel Therapeutics by 7.5% during the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after acquiring an additional 13,952 shares during the period. Finally, Northern Trust Corp raised its stake in BioXcel Therapeutics by 81.4% during the 4th quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock worth $28,000 after acquiring an additional 33,161 shares during the period. Institutional investors own 30.68% of the company’s stock. Analyst Upgrades and Downgrades A number of research firms have commented on BTAI. Wall Street Zen upgraded shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Rodman & Renshaw began coverage on shares of BioXcel Therapeutics in a research note on Wednesday, March 19th. They set a “buy” rating and a $65.00 target price on the stock. Finally, RODMAN&RENSHAW upgraded shares of BioXcel Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.60. View Our Latest Report on BTAI BioXcel Therapeutics Price Performance BioXcel Therapeutics stock opened at $1.99 on Wednesday. The stock has a market cap of $12.05 million, a P/E ratio of -0.06 and a beta of -0.12. BioXcel Therapeutics, Inc. has a 1 year low of $1.17 and a 1 year high of $25.12. The firm’s 50 day moving average price is $1.61 and its 200-day moving average price is $3.49. BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.72) by $1.22. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.35 million. As a group, equities analysts expect that BioXcel Therapeutics, Inc. will post -24.39 EPS for the current year. BioXcel Therapeutics Company Profile (Free Report) BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.» Mehr auf defenseworld.net

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia continue without modification.» Mehr auf globenewswire.com

NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the Company's request to continue its listing on The Nasdaq Stock Market.» Mehr auf globenewswire.com